Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8SKU1)

Drug Name
SR9009 Drug Info
Synonyms
1379686-30-2; SR-9009; Stenabolic (SR9009); SR 9009; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate; CHEMBL1961796; 1-Pyrrolidinecarboxylic acid, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-, ethyl ester; 1-pyrrolidinecarboxylic acid, 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-, ethyl ester; GTPL8901; EX-A726; BCP16215; BDBM50366238; MFCD29472236; s8692; AKOS027470307; CCG-269102; CS-4669; DB14013; SB19006; NCGC00384202-01; AC-30219; AK547297; AS-55859; HY-16989; J-690150; Q15410184; N'-[(1E)-1-(5-Chloro-2-hydroxyphenyl)ethylidene]-3-(4-morpholinylsulfonyl)benzohydrazide; ethyl 3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitro-2-thienyl)methyl]amino]methyl]pyrrolidine-1-carboxylate; Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
57394020
CAS Number
CAS 1379686-30-2
TTD Drug ID
DM8SKU1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting V-erbA-related protein 1 (NR1D1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GSK4112 DM1S5UO Inflammation 1A00-CA43.1 Preclinical [3]
SR8278 DMSK5N3 Myocardial disease BC43.20 Preclinical [3]
SR9011 DMZ9BO8 Solid tumour/cancer 2A00-2F9Z Preclinical [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
V-erbA-related protein 1 (NR1D1) TTAD1O8 NR1D1_HUMAN Agonist [2]

References

1 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2 Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355.
3 Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol. 2011 Feb 18;6(2):131-4.